UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc ...

a retina specialist at Northern California Retina Vitreous Associates, in Mountain View, and an associate clinical professor ...

NY Retina, a newly launched ophthalmology practice, is set to open March 20 in a newly purchased medical office building in ...

A long time ago, my kids taught me that the importance of pain depends upon whether you are the one giving it or the one ...

SMU nanotechnology expert MinJun Kim is working with Applied Research Associates, Inc. to develop microrobots that could ...

Retinal re-detachment following cataract extraction remains significant in patients who have previously undergone pars plana ...

More than 230 ASCs were recognized as “high performing” in the field of ophthalmology, according to U.S. News & World Report’‘s annual “Best Ambulatory Surgery Centers” list. U.S. News evaluated 1,910 ...